» Articles » PMID: 31200864

Ligand-induced Genetic Degradation As a Tool for Target Validation

Overview
Publisher Elsevier
Date 2019 Jun 16
PMID 31200864
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Targeted protein degraders, known as proteolysis targeting chimeras (PROTACs), are drawing more attention as next-generation drugs to target currently undruggable proteins. As drug discovery of functional degraders involves time- and cost-consuming laborious processes, we propose employing a ligand-induced genetic degradation system to validate candidate proteins before degrader development. Genetic degradation mimics degrader treatment by depleting a degron-fused protein in the presence of a defined ligand. All genetic systems use a combination of a degron and defined ligand that enables a protein of interest fused with the degron to be recruited to an E3 ubiquitin ligase for ubiquitylation and subsequent degradation by the proteasome. However, these events are based on different principles and have different features. We review the dTAG, HaloTag-based, auxin-inducible degron (AID), and destabilizing domain (DD) systems and discuss a strategy for degrader discovery against novel target proteins.

Citing Articles

Inducing Receptor Degradation as a Novel Approach to Target CC Chemokine Receptor 2 (CCR2).

Ortiz Zacarias N, Roth S, Broekhuis J, van der Es D, Moreau K, Heitman L Int J Mol Sci. 2024; 25(16).

PMID: 39201670 PMC: 11354370. DOI: 10.3390/ijms25168984.


PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas.

Mancarella C, Morrione A, Scotlandi K Int J Mol Sci. 2023; 24(22).

PMID: 38003535 PMC: 10671294. DOI: 10.3390/ijms242216346.


Phosphoproteomic Approaches for Identifying Phosphatase and Kinase Substrates.

DeMarco A, Hall M Molecules. 2023; 28(9).

PMID: 37175085 PMC: 10180314. DOI: 10.3390/molecules28093675.


A Perspective on Newly Emerging Proteolysis-Targeting Strategies in Antimicrobial Drug Discovery.

Venkatesan J, Murugan D, Rangasamy L Antibiotics (Basel). 2022; 11(12).

PMID: 36551374 PMC: 9774230. DOI: 10.3390/antibiotics11121717.


Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.

Diehl C, Ciulli A Chem Soc Rev. 2022; 51(19):8216-8257.

PMID: 35983982 PMC: 9528729. DOI: 10.1039/d2cs00387b.